Tumor-associated urokinase-type plasminogen activator: significance in breast cancer.

Torre, E A; Fulco, R A

Torre, E A; Fulco, R A.

Afiliación

Torre EA; Biomedical Technology Section, Scientific Oncologic Institute of Genova, Oncologic Institute of Messina Italy.

Eur J Gynaecol Oncol ; 17(4): 315-8, 1996.

Article en En | MEDLINE | ID: mdl-8856315

RESUMEN

Urokinase-type plasminogen activator (u-PA), a proteolitic enzyme, capable of degrading type 4 collagen, is supposed to be involved in degradation of extracellular matrix during cancer invasion. Evidence has been presented that primary breast cancer patients with tumors containing high levels of u-PA experience a worse prognosis. u-PA and its inhibitor, type 1 plasminogen activator inhibitor (PAI-1), are potentially important prognostic factors in breast cancer to identify patients at high risk for recurrence and also in the classification of clinically important subgroups.

Asunto(s)

Neoplasias de la Mama/enzimología; Activador de Plasminógeno de Tipo Uroquinasa/metabolismo; Humanos; Pronóstico

Buscar en Google

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Activador de Plasminógeno de Tipo Uroquinasa Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Eur J Gynaecol Oncol Año: 1996 Tipo del documento: Article Pais de publicación: Singapur

Buscar en Google

Añadir a Mi BVS

Imprimir

XML

PubMed Links